Saniona Investor Relations Material
Latest events
Status Update
Saniona
Q1 2025
28 May, 2025
Q4 2024
27 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Saniona
Access all reports
Saniona AB is a clinical-stage biopharmaceutical company based in Denmark, focused on the discovery and development of treatments for central nervous system, autoimmune, metabolic diseases, and pain management. The company specializes in modulating ion channels, a class of proteins critical in cellular signaling. Saniona has built a proprietary drug discovery platform that includes more than 20,000 ion channel-modulating molecules. The company is headquartered in Ballerup, Denmark, and its shares are listed on the Nasdaq Stockholm.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
SANION
Country
🇸🇪 Sweden